Skip to main content
VECTUS BIOSYSTEMS LIMITED logo

VECTUS BIOSYSTEMS LIMITED — Investor Relations & Filings

Ticker · VBS ISIN · AU000000VBS9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 315 across all filing types
Latest filing 2019-04-29 Interim / Quarterly Rep…
Country AU Australia
Listing ASX VBS

About VECTUS BIOSYSTEMS LIMITED

https://vectusbiosystems.com.au/

Vectus Biosystems Limited is a drug discovery and development company focused on creating therapeutic candidates for the treatment of fibrosis and hypertension. The company utilizes a proprietary library of mimetic compounds to address tissue scarring and organ damage in the heart, kidneys, and liver. Its lead drug candidate, VB0004, is designed to treat high blood pressure and reverse established fibrosis. Complementing its pharmaceutical research, the company developed the Accugen platform, which provides a system for the precise quantification of DNA and RNA through quantitative polymerase chain reaction (qPCR) technology. By focusing on the reversal of fibrotic damage rather than symptom management, the company seeks to address significant unmet needs in chronic disease management and regenerative medicine.

Recent filings

Filing Released Lang Actions
Appendix 4C - quarterly 6 pages 395.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY REPORT – APPENDIX 4C' and references compliance with ASX Listing Rule 4.7B, which pertains to quarterly reporting requirements for entities listed on the Australian Securities Exchange. The content includes detailed financial data such as consolidated cash flow statements for the quarter ended 31 March 2019, commentary on company activities, and cash flow reconciliations. The document length is over 12,000 characters, indicating it is a substantive report rather than a brief announcement. The presence of actual financial statements and analysis for a period shorter than a full fiscal year confirms this is an Interim / Quarterly Report. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). Q3 2019
2019-04-29 English
Half Year Report and Appendix 4D 18 pages 1.1MB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Half-Year Report' and references financial results for the half-year ended 31 December 2018. It includes detailed financial statements such as the condensed consolidated statement of profit or loss, statement of financial position, directors' report, auditor's review report, and notes to the financial statements. The presence of comprehensive financial data and analysis for a period shorter than a full fiscal year (six months) confirms it is an interim or quarterly report. The document is lengthy (15,000 characters) and contains substantive financial information, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2019
2019-02-27 English
Response to ASX Appendix 4C Query 4 pages 688.5KB
Regulatory Filings Classification · 95% confidence The document is a letter from Vectus Biosystems Limited responding to a query from ASX Compliance regarding the company's December 2018 Appendix 4C Quarterly Report. The letter addresses questions about the company's negative operating cash flows, fundraising plans, ability to continue operations, compliance with ASX Listing Rules, and financial condition. The document references the Appendix 4C Quarterly Report but does not contain the report itself or detailed financial statements. Instead, it is a regulatory response letter to ASX's request for information under Listing Rule 18.7. The document is over 11,000 characters, indicating it is not a brief announcement but a detailed compliance response. Given the nature of the content—responses to regulatory inquiries about financial condition and compliance—and the absence of actual financial statements or comprehensive financial analysis, this document fits best under Regulatory Filings (RNS), which is the fallback category for compliance letters and regulatory correspondence that do not fit other specific report types.
2019-02-21 English
Appendix 4C - Quarterly Report 6 pages 396.5KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'QUARTERLY REPORT – APPENDIX 4C' and references compliance with ASX Listing Rule 4.7B, which pertains to quarterly reporting for entities listed on the Australian Securities Exchange. The content includes detailed financial data such as consolidated cash flow statements, cash reconciliation, financing facilities, and estimated cash outflows for the next quarter. It also contains commentary on company activities during the quarter, patent updates, trade engagement, and financing status. The document length is over 11,000 characters, indicating it is a substantive report rather than a brief announcement. The presence of actual financial statements and analysis for a period shorter than a full fiscal year confirms it is an Interim / Quarterly Report. Therefore, the appropriate classification is 'IR' (Interim / Quarterly Report). Q2 2019
2019-01-30 English
Chairman's Address to Shareholders 2 pages 226.2KB
AGM Information Classification · 95% confidence The document is titled 'Chairman’s Address to 14 November 2018 Annual General Meeting' and contains a detailed address from the Chairman discussing company progress, funding strategies, clinical trial milestones, patent status, and acknowledgments to the team and directors. It is clearly a speech or presentation given at the AGM rather than a formal report such as an Annual Report (10-K) or Interim Report (IR). The content focuses on company updates and strategic outlook typical of AGM presentations. The document length is about 5,074 characters, which is consistent with a detailed AGM address. There is no indication that this is a full financial report or regulatory filing. Therefore, the most appropriate classification is AGM Information (AGM-R).
2018-11-13 English
CEO's Address to Shareholders 23 pages 2.9MB
Investor Presentation Classification · 95% confidence The document is a detailed presentation about a pharmaceutical company's drug candidates targeting fibrosis, including scientific data, preclinical results, safety studies, intellectual property, and clinical trial plans. It contains extensive information on the drug's mechanism, efficacy in animal models, safety data, synthesis scale, patent status, and upcoming Phase 1 clinical trials. There is no indication that this is a regulatory filing, earnings release, or annual report. The content is educational and promotional, aimed at investors or stakeholders to explain the company's technology and market potential. This matches the description of an Investor Presentation (IP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2018-11-13 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.